Page last updated: 2024-12-08

monodesmethylcitalopram

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

monodesmethylcitalopram: metabolite of citalopram [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162180
CHEMBL ID1649
CHEBI ID80603
SCHEMBL ID2738827
MeSH IDM0153677

Synonyms (36)

Synonym
demethylcitalopram
62498-67-3
monodesmethylcitalopram
1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile
FT-0665694
FT-0666108
chebi:80603 ,
CHEMBL1649
demethyl-citalopram
1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-3h-2-benzofuran-5-carbonitrile
3kbx9104ir ,
unii-3kbx9104ir
einecs 263-573-8
desmethylcitalopram
cas_144025-14-9
bdbm85219
lu 11-109
citalopram hydrochloride impurity d [ep impurity]
rac-desmethylcitalopram
norcitalopram
citalopram hydrobromide impurity d [ep impurity]
1-(4-fluorophenyl)-1-(3-methylaminopropyl)-1,3-dihydroisobenzofuran-5-carbonitrile
5-isobenzofurancarbonitrile, 1-(4-fluorophenyl)-1,3-dihydro-1-(3-(methylamino)propyl)-
(+/-)-n-demethylcitalopram
SCHEMBL2738827
(rs/s)-1-[3-(methylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
n-desmethylcitalopram
discontinued see: d230846
1-(4-fluorophenyl)-1,3-dihydro-1-[3-(methylamino)propyl]-5-isobenzofurancarbonitrile
Q5264610
1-[3-(methylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3- dihydro-2-benzofuran-5-carbonitrile
1-(4-fluorophenyl)-1-(3-(methylamino)propyl)-1,3-dihydroisobenzofuran-5-carbonitrile
(r)-(-)-desmethyl citalopram
DTXSID90881082
rac demethyl citalopram

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Comparable pharmacokinetic variability was noted for (+)-(S)-, (-)-(R)- and rac-citalopram."( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.
Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997
)
0.3
" Validation results and its application to the analysis of plasma samples after oral administration of citalopram in healthy Chinese volunteers demonstrated the method was applicable to pharmacokinetic studies."( Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study.
Chen, B; Chen, C; Chen, H; Jiang, T; Lu, Y; Peng, L; Rong, Z; Sun, J; Xie, Y; Xu, Y, 2010
)
0.36
" The half-life of the racemic mixture of citalopram after intragastric administration was increased by about 287%."( Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers.
Florek, E; Jawien, W; Kulza, M; Majcherczyk, J; Piekoszewski, W; Senczuk-Przybylowska, M, 2012
)
0.38
" A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and S-citalopram and their primary metabolite (desmethylcitalopram)."( A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
Akil, A; Avramopoulos, D; Bies, RR; Devanand, DP; Lyketsos, CG; Mintzer, JE; Pollock, BG; Porsteinsson, AP; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Several models for the absorption rate were explored (e."( A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats.
Bender, DM; Bies, RR; Eastwood, B; Jackson, K; Lowe, S; Swanson, S; Velez de Mendizabal, N, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Enantiomeric (S/R) serum concentration ratios for citalopram were always less than unity and were constant during the steady-state dosing interval."( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.
Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997
)
0.3
"The AUC of S-, but not R-(CT) was found to be significantly higher in PM of mephenytoin compared to EMs, PMs may need a lower dosage of CT."( Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.
Bertilsson, L; Gustafsson, LL; Herrlin, K; Tybring, G; Widén, J; Yasui-Furukori, N, 2003
)
0.32
"It is important that variations in drug metabolism during pregnancy be considered as these changes may necessitate a dosage adjustment to ensure that therapeutic failure does not occur during pregnancy."( Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach.
Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic amino compoundA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Citalopram and Escitalopram Pathway, Pharmacokinetics44
Citalopram Action Pathway3724
Citalopram Metabolism Pathway715

Bioassays (2)

Assay IDTitleYearJournalArticle
AID408252Inhibition of [3H]dopamine reuptake at human NET expressed in african green monkey COS7 cells at 100 nM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
AID408251Inhibition of [3H]5-hydroxytryptamine reuptake at human SERT expressed in african green monkey COS7 cells at 100 nM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (6.12)18.7374
1990's7 (14.29)18.2507
2000's18 (36.73)29.6817
2010's19 (38.78)24.3611
2020's2 (4.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.91 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]